PGNY Stock: Price, Earnings History and SEC Filings
Progyny, Inc. (PGNY) last traded at $29.19, up 2.78% on the latest session and up 15.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.34 against an analyst estimate of $0.28, a beat of 21.4%.
$29.19 +2.78%
1 month+15.88%
52-week high$33.07
52-week low$16.10
Volume807,727
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PGNY earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.34 | $0.28 | +21.43% |
| Mar 2026 | May 7, 2026 | $0.29 | $0.24 | +20.83% |
| Dec 2025 | Feb 26, 2026 | $0.14 | $0.13 | +7.69% |
| Sep 2025 | Nov 6, 2025 | $0.15 | $0.13 | +15.38% |
PGNY beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
PGNY financial history
Revenue
Net income
Free cash flow
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.3B | $59M | $192M | 4.5% | $0.65 |
| 2024 | $1.2B | $54M | $174M | 4.7% | $0.57 |
| 2023 | $1.1B | $62M | $185M | 5.7% | $0.62 |
| 2022 | $787M | $30M | $77M | 3.9% | $0.30 |
| 2021 | $501M | $66M | $24M | 13.1% | $0.66 |
| 2020 | $345M | $46M | $35M | 13.5% | $0.47 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PGNY
SEC filing data is not available right now. You can search for PGNY on SEC EDGAR.
PGNY news
- Progyny (PGNY) Cuts Guidance And Puts Its Valuation Back In FocusNov 1, 2026 · finance.yahoo.com
- Progyny (PGNY) Stock Looks About Right On Its 56% RunNov 1, 2026 · finance.yahoo.com
- Is Lower Revenue Guidance Altering The Investment Case For Progyny Stock (PGNY)?Nov 1, 2026 · finance.yahoo.com
- Progyny’s (PGNY) Full-Year Guidance Lowered on Utilization HeadwindsOct 30, 2026 · finance.yahoo.com
- Progyny stock study finds treatment gaps persist despite benefitsOct 29, 2026 · ad-hoc-news.de
- 1 cash-producing stock for long-term investors and 2 we find riskyOct 29, 2026 · finance.yahoo.com
- 3 Reasons to sell PGNY and 1 stock to buy insteadOct 28, 2026 · finance.yahoo.com
- New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to BenefitsOct 28, 2026 · finance.yahoo.com
About Progyny, Inc.
Progyny, Inc. (PGNY) is a US-listed public company on Nasdaq.